New York Blood Center Enterprises buys Talaris’ cell therapy facilities in CDMO expansion

Anna Brown

News Reporter

The New York Blood Center Enterprises (NYBCe) is absorbing two of Talaris Therapeutics’ autologous and allogeneic cell and gene therapy facilities to expand its CDMO …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

New York Blood Center Enterprises buys Talaris’ cell therapy facilities in CDMO expansion

Anna Brown

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Immatics loses Bristol Myers' support on Phase 1 bispecific T cell engager

Breaking down silos with a new quantitative approach to drug development

New York Blood Cen­ter En­ter­pris­es buys Ta­laris’ cell ther­a­py fa­cil­i­ties in CD­MO ex­pan­sion

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

New York Blood Center Enterprises buys Talaris’ cell therapy facilities in CDMO expansion